• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Remibrutinib alleviates symptoms in chronic spontaneous urticaria resistant to H1-antihistamines

byAnna YangandKiera Liblik
March 13, 2025
in Chronic Disease, Dermatology
Reading Time: 3 mins read
Clinical care collage: a smiling clinician in a white coat with a stethoscope around her neck beside a blank clipboard
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation H1-antihistamines, it was found that remibrutinib more effectively reduced itching and hives compared with placebo.

2. Adverse events among patients who received remibrutinib were generally similar to those in the placebo group, with most adverse events being mild or moderate.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Chronic spontaneous urticaria is characterized by itch, hives, or angioedema that recur unpredictably for over six weeks without any specific triggers. Second-generation H1-antihistamines are currently the first-line treatment, but over 50% of patients receiving H1-antihistamines continue to experience symptoms. International guidelines recommend the addition of an anti-IgE biologic agent as a second-line treatment if chronic spontaneous urticaria remains uncontrolled with H1-antihistamines. Remibrutinib is an oral, highly selective Bruton’s tyrosine kinase (BTK) inhibitor that blocks BTK-mediated degranulation of mast cells and basophils, thus preventing the release of histamine and other pro-inflammatory mediators that lead to the itch, hives, and angioedema seen in chronic spontaneous urticaria. Remibrutinib has been shown in phase 2b studies to be both effective and safe. The present trial assessed the efficacy and safety of remibrutinib as an add-on treatment compared with a placebo among patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation H1-antihistamines. Compared with placebo, remibrutinib was more effective in reducing itching and hives. Additionally, remibrutinib was found to be safe, with adverse events being similar between the two groups and most adverse events being mild or moderate. Limitations of the study included its failure to account for the effects of background medication and additional rescue medications, which might have contributed to the decrease in symptoms seen in the placebo group. Nevertheless, these findings serve as a valuable step in demonstrating the clinical value of remibrutinib as a second-line treatment for chronic spontaneous urticaria in patients whose disease remains uncontrolled on H1-antihistamines.

Click to read the study in the NEJM (New England Journal of Medicine)

In-Depth [randomized controlled trial]: This phase three, double-blind, randomized trial assessed the efficacy and safety of remibrutinib compared with placebo as an add-on treatment in patients with chronic spontaneous urticaria who continue to have symptoms while on second-generation H1-antihistamines. Patients 18 years of age or older with a diagnosis of chronic spontaneous urticaria who have remained symptomatic during treatment with second-generation H1-antihistamines were included. The primary outcome was the change in urticaria activity score during a 7-day period (UAS7) from baseline to week 12. A total of 918 patients were included in the study, with 606 assigned to the remibrutinib group and 306 assigned to the placebo group. At 12 weeks, improvement in UAS7 was significantly greater in the remibrutinib group compared with placebo. The percentage of patients with well-controlled urticaria was also higher with remibrutinib than with placebo at week two (33.7% vs 3.3%; odds ratio, 15.7; 95% Confidence Interval [CI], 6.2 to 39.8; p<0.001), and the complete absence of itch and hives occurred in more patients in the remibrutinib group than in the placebo group at week 12 (31.1% vs 10.5%; odds ratio, 3.8; 95% CI, 2.2 to 6.8; p<0.001). With regards to safety, the percentage of patients with any adverse effect was similar between the groups (64.9% and 64.7%, respectively), with most adverse events being mild or moderate. Laboratory measures were typically within normal limits, with outliers being similar between the groups. In summary, among patients with chronic spontaneous urticaria who continue to have symptoms despite treatment with second-generation H1-antihistamines, remibrutinib was shown to be safe and more effective compared with placebo, as assessed via a composite weekly measure of itching and hives.

RELATED REPORTS

Atopic dermatitis activity is not associated with cardiovascular risk

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: chronic diseasechronic spontaneous urticariadermatologyH1-antihistaminesRemibrutinib
Previous Post

Acute hallucinogen use demonstrates increased in-hospital mortality

Next Post

Low-dose yellow fever vaccine non-inferior to standard dose

RelatedReports

Eczema more prevalent among older adults than previously thought
Cardiology

Atopic dermatitis activity is not associated with cardiovascular risk

April 2, 2026
Medicines in clinical trials collage: a plain white pharmacy bag with a folded top beside capsules and round tablets
All Specialties

Oral remibrutinib hits Phase 3 primary endpoint for inducible hives

March 5, 2026
2 Minute Medicine: Pharma Roundup: Price Hikes, Breakthrough Approvals, Legal Showdowns, Biotech Expansion, and Europe’s Pricing Debate [May 12nd, 2025]
Chronic Disease

2 Minute Medicine: Pharma Roundup – Merck and Mayo Clinic’s AI precision medicine lab, Novartis’ remibrutinib hits Phase III hive endpoint, FDA grants priority review for iberdomide in myeloma, oral infigratinib boosts growth velocity in achondroplasia, and shingles vaccine/sildenafil linked to lower Alzheimer’s risk [February 2026]

February 26, 2026
Solitary kidney not associated with contrast-induced nephropathy
Chronic Disease

Albuminuria shows a stronger association with kidney failure than proteinuria

November 20, 2025
Next Post
Adult vaccination collage: a smiling older man with a bandage on his upper arm, a vaccine vial, a cooler bag and antibodies

Low-dose yellow fever vaccine non-inferior to standard dose

Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes

Glucagon-like Peptide-1 Receptor Agonists and Lower Depression Risk in Older Adults with Diabetes

Liver cancer immunotherapy collage: an engraved liver and gallbladder with round immune cells at its edge and a potted fern

Durvalumab and bevacizumab plus chemoembolization improves progression-free survival in hepatocellular carcinoma

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cretostimogene reduced recurrence risk in intermediate-risk and high-grade Ta non-muscle invasive bladder cancer in topline phase 3 results
  • Removing Race and Ethnicity From Dialysis Mortality Risk Adjustment Changes Facility Performance Rankings
  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.